...experiences with another platform company - bispecific mAb developer Covagen AG . "We were the founding Covagen... ...is in preclinical development for cancer, putting it on about the same schedule as Covagen... ...when the company has preclinical assets, and entering the clinic about seven years after inception. Covagen...
...simultaneously to two different epitopes on HER2. The program, gained through the August acquisition of Covagen AG... ...scFv) joined by synthetic linker AFM13 to start Ph IIa for Hodgkin's disease in 4Q14 Covagen AG...
...Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's... ...Sciences Ltd., said Covagen's sale will return a greater than 6x multiple. Gilles Nobécourt of Covagen... ...Funds serves on the jury, which is how the firm first became involved with Covagen. Covagen...
...& Johnson’s Cilag GmbH International subsidiary acquired mAb platform company Covagen for an undisclosed amount. Covagen... ...are based on Fyn SH3-derived binding protein, a naturally occurring human protein scaffold. In May, Covagen... ...of tumor necrosis factor (TNF) and IL-17A . J&J’s London Innovation Center coordinated the deal. Covagen AG...
...Johnson & Johnson (NYSE:JNJ) acquired mAb platform company Covagen AG (Zurich, Switzerland) for an undisclosed amount. Covagen... ...based on Fyn SH3-derived binding protein , a naturally occurring human protein scaffold. In May, Covagen... ...of tumor necrosis factor (TNF) and IL-17A . J&J's London Innovation Center coordinated the deal. Covagen...
...evaluate single ascending-doses of COVA322 in about 39 patients with psoriasis. COVA322 was developed using Covagen's... ...technology. Fynomers are based on the naturally occurring human protein scaffold Fyn SH3-derived binding protein. Covagen AG...
...Baxter Ventures in the second close of a CHF44.9 million ($50.3 million) series B round. Covagen... ...the company said it secured CHF42 million ($47.1 million) in the tranched series B round. Covagen... ...met. The company declined to disclose how much of the funding it has already received. Covagen AG...
...experiences with another platform company - bispecific mAb developer Covagen AG . "We were the founding Covagen... ...is in preclinical development for cancer, putting it on about the same schedule as Covagen... ...when the company has preclinical assets, and entering the clinic about seven years after inception. Covagen...
...simultaneously to two different epitopes on HER2. The program, gained through the August acquisition of Covagen AG... ...scFv) joined by synthetic linker AFM13 to start Ph IIa for Hodgkin's disease in 4Q14 Covagen AG...
...Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's... ...Sciences Ltd., said Covagen's sale will return a greater than 6x multiple. Gilles Nobécourt of Covagen... ...Funds serves on the jury, which is how the firm first became involved with Covagen. Covagen...
...& Johnson’s Cilag GmbH International subsidiary acquired mAb platform company Covagen for an undisclosed amount. Covagen... ...are based on Fyn SH3-derived binding protein, a naturally occurring human protein scaffold. In May, Covagen... ...of tumor necrosis factor (TNF) and IL-17A . J&J’s London Innovation Center coordinated the deal. Covagen AG...
...Johnson & Johnson (NYSE:JNJ) acquired mAb platform company Covagen AG (Zurich, Switzerland) for an undisclosed amount. Covagen... ...based on Fyn SH3-derived binding protein , a naturally occurring human protein scaffold. In May, Covagen... ...of tumor necrosis factor (TNF) and IL-17A . J&J's London Innovation Center coordinated the deal. Covagen...
...evaluate single ascending-doses of COVA322 in about 39 patients with psoriasis. COVA322 was developed using Covagen's... ...technology. Fynomers are based on the naturally occurring human protein scaffold Fyn SH3-derived binding protein. Covagen AG...
...Baxter Ventures in the second close of a CHF44.9 million ($50.3 million) series B round. Covagen... ...the company said it secured CHF42 million ($47.1 million) in the tranched series B round. Covagen... ...met. The company declined to disclose how much of the funding it has already received. Covagen AG...
